Commonwealth Equity Services LLC lifted its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS – Free Report) by 31.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 130,785 shares of the company’s stock after purchasing an additional 30,933 shares during the period. Commonwealth Equity Services LLC owned approximately 0.06% of Hims & Hers Health worth $4,247,000 at the end of the most recent reporting period.
A number of other hedge funds have also recently bought and sold shares of HIMS. Flagship Harbor Advisors LLC bought a new position in Hims & Hers Health in the 4th quarter valued at $28,000. Binnacle Investments Inc bought a new position in Hims & Hers Health in the 3rd quarter valued at $28,000. Bogart Wealth LLC boosted its position in Hims & Hers Health by 235.8% in the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after buying an additional 632 shares during the last quarter. Geneos Wealth Management Inc. bought a new position in Hims & Hers Health in the 1st quarter valued at $30,000. Finally, Entrust Financial LLC acquired a new stake in Hims & Hers Health in the fourth quarter worth about $47,000. 63.52% of the stock is currently owned by institutional investors.
Hims & Hers Health Stock Performance
Shares of HIMS opened at $26.25 on Monday. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69. Hims & Hers Health, Inc. has a twelve month low of $13.74 and a twelve month high of $70.43. The firm’s 50 day moving average price is $24.61 and its two-hundred day moving average price is $27.02. The firm has a market cap of $6.08 billion, a P/E ratio of -291.71, a PEG ratio of 49.14 and a beta of 2.37.
Analyst Ratings Changes
A number of analysts recently commented on the company. Bank of America lowered their price objective on Hims & Hers Health from $28.00 to $25.00 and set a “neutral” rating for the company in a research report on Tuesday, May 26th. Citigroup lifted their price objective on Hims & Hers Health from $24.00 to $28.00 and gave the stock a “neutral” rating in a research report on Tuesday, May 12th. Truist Financial boosted their price target on shares of Hims & Hers Health from $18.00 to $23.00 and gave the stock a “hold” rating in a research note on Friday, May 22nd. Wall Street Zen downgraded shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, May 9th. Finally, BTIG Research reissued a “neutral” rating on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Four analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $28.70.
Get Our Latest Stock Report on Hims & Hers Health
Insider Transactions at Hims & Hers Health
In related news, insider Irene Becklund sold 5,529 shares of the company’s stock in a transaction on Tuesday, March 17th. The shares were sold at an average price of $24.69, for a total value of $136,511.01. Following the completion of the transaction, the insider directly owned 8,752 shares of the company’s stock, valued at approximately $216,086.88. This represents a 38.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director David B. Wells bought 48,400 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, May 26th. The stock was bought at an average cost of $24.23 per share, with a total value of $1,172,732.00. Following the completion of the purchase, the director owned 224,417 shares in the company, valued at approximately $5,437,623.91. This trade represents a 27.50% increase in their position. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders sold 212,807 shares of company stock worth $5,473,644. Company insiders own 11.76% of the company’s stock.
Hims & Hers Health Profile
Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.
The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.
Featured Articles
- Five stocks we like better than Hims & Hers Health
- These 3 Insurance Stocks Made New 52-Week Highs: Still Time to Buy?
- 3 Stocks Under $20 to Buy Before a Broader Market Rally
- Petco Faces Tough Competition, But Momentum Is Building
- The Lock-In Effect Is Real—These 3 Homebuilders Are Betting on It
Want to see what other hedge funds are holding HIMS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hims & Hers Health, Inc. (NYSE:HIMS – Free Report).
Receive News & Ratings for Hims & Hers Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hims & Hers Health and related companies with MarketBeat.com's FREE daily email newsletter.
